Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy
| Autor: | Friederike Jochimsen, Marina Stoffler-Meilicke, Walter Zidek, Wolfram H. Gerlich, Alexander Schmittel, Timm H. Westhoff, Jurgen H Schafer, Eckhard Thiel |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Hepatitis B virus
Fatal outcome biology business.industry Immunology Mutant Cell Biology Hematology medicine.disease medicine.disease_cause Biochemistry Virology Lymphoma immune system diseases Rituximab therapy hemic and lymphatic diseases Monoclonal medicine biology.protein Rituximab Antibody business medicine.drug |
| Zdroj: | Blood. 102:1930-1930 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | The chimeric monoclonal anti-CD20 antibody rituximab targets and destroys B lymphocytes and is used increasingly in the treatment of B-cell non-Hodgkin lymphoma.[1][1],[2][2] In spite of rituximab-induced B-cell depletion, the incidence of infectious complications does not appear to be generally |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|